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Abstract
Background:  General practitioners' (GPs) diagnostic skills lead to underidentification of
generalized anxiety disorders (GAD) and major depressive episodes (MDE). Supplement of brief
questionnaires could improve the diagnostic accuracy of GPs for these common mental disorders.
The aims of this study were to examine the usefulness of The Hospital Anxiety and Depression
Rating Scale (HADS) for GPs by: 1) Examining its psychometrics in the GPs' setting; 2) Testing its
case-finding properties compared to patient-rated GAD and MDE (DSM-IV); and 3) Comparing its
case finding abilities to that of the GPs using Clinical Global Impression-Severity (CGI-S) rating.
Methods: In a cross-sectional survey study 1,781 patients in three consecutive days in September
2001 attended 141 GPs geographically spread in Norway. Sensitivity, specificity, optimal cut off
score, and Area under the curve (AUC) for the HADS and the CGI-S were calculated with
Generalized Anxiety Questionnaire (GAS-Q) as reference standard for GAD, and Depression
Screening Questionnaire (DSQ) for MDE.
Results: The HADS-A had optimal cut off ≥8 (sensitivity 0.89, specificity 0.75), AUC 0.88 and 76%
of patients were correctly classified in relation to GAD. The HADS-D had by optimal cut off ≥8
(sensitivity 0.80 and specificity 0.88) AUC 0.93 and 87% of the patients were correctly classified in
relation to MDE. Proportions of the total correctly classified at the CGI-S optimal cut-off ≥3 were
83% of patients for GAD and 81% for MDE.
Conclusion: The results indicate that addition of the patients' HADS scores to GPs' information
could improve their diagnostic accuracy of GAD and MDE.
Background
An important task for general practitioners (GPs) is to
diagnose and treat depressions and anxiety disorders,
which are among the most common and amenable men-
tal disorders in their practice [1]. The literature shows that
the GPs' diagnostic skills concerning these common disor-
ders are moderately good [1-8], and somewhat better for
major depressive episodes (MDE) than for generalized
anxiety disorder (GAD) [8]. A prospective cohort study of
depression in primary care, found that the WHO-5 well
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being index (WHO-5, 5 items) had significantly higher
sensitivity than the GPs' clinical diagnosis when the Com-
posite International Diagnostic Interview (CIDI) was used
as gold standard [9]. The depression module of the brief
patient health questionnaire (B-PHQ, 9 items) had signif-
icantly higher specificity than GPs' clinical diagnoses, and
GPs' diagnoses had significantly higher specificity than
the WHO-5. The sensitivity and specificity of screening
instruments for GAD in general practice has hardly been
investigated [10,11].
Reviews [12,13] show that the Hospital Anxiety and
Depression Rating Scale (HADS) [14] is widely used as a
brief self-rating instrument for both dimensional and cat-
egorical aspects of anxiety and depression in both epide-
miology and specialist care. In these settings the
psychometric properties of the HADS are excellent
[15,16]. Until now the factor structure, the internal con-
sistency, and the inter-correlation and homogeneity of the
HADS sub-scales have not been described in the context
of general practice. The case-finding abilities of the HADS
in relation to DSM-III/DSM-IV and ICD-10 defined anxi-
ety disorders and depressions by the use of a score ≥ 8 as
cut-off are considered good with few false negatives, but a
definite proportion of false positives. In clinical practice a
positive screening typically results in further evaluation.
Considering the brevity and feasibility of the HADS, it
should be useful for screening of patients in general prac-
tice, but studies of the HADS from that part of the health
services are few and inconsistent as to cut-off scores for
caseness [17-20]. These points indicate the need for more
data on the case-finding abilities of the HADS subscales in
general practice.
Aims of the study
This study from Norwegian general practice has the fol-
lowing aims: 1) To examine the psychometric features of
the HADS rated by patients in the primary care setting; 2)
To test the case-finding properties of the HADS in relation
to the diagnoses of GAD and MDE based on patient-rating
of their diagnostic criteria according to DSM-IV as refer-
ence standards; and 3) To compare the case finding abili-
ties of the HADS rated by patients to that of GPs using the
Clinical Global Impression-Severity (CGI-S).
Methods
Procedure
The study is based on a cross-sectional study of GP's and
their patients carried out in Germany, Scandinavia, and
Finland [8,21]. A flow-chart over the study design is
shown in Figure 1. Essential features of the design were: 1)
Sampling of GPs geographically spread in Norway; 2)
During three consecutive days in September 2001 all the
GPs' patients were invited to take part in a study rating
themselves on the three questionnaires concerning anxi-
ety and depression;. 3) Blind to the patients' ratings, the
GPs filled in the CGI-S in order to rate the clinical severity
of eventual GAD and MDE in their patients. Exclusion cri-
teria for patients were: age < 16 years, language difficul-
ties, patients who required help to complete the
questionnaires, and patients who came for prescription
only, or for an accident/emergency.
Sampling of GPs
The GPs in various parts of Norway were recruited as a
convenience sample among those registered in the data-
base of Wyeth Norway Ltd. The procedural information to
the GPs was given in writing, and no special training of
them for the study was undertaken. Among 141 partici-
pating GPs, 136 were eligible and 133 gave demographic
data. Ninety GPs (68%) were men and 43 (32%) women.
They had been working in primary care for a mean of 15
(SD 7) and 11 (SD 7) years, respectively, and 118 (89%)
of them worked in group practice. The GPs consulted with
a mean of 21.1 (SD 5.1) patients on an average day. There
were no significant differences between genders of GPs
with regard to number of consultations.
Sampling of patients
Among the 1,781 patients included in the study, 1,385
(78 %) had valid ratings on the DSQ and the HADS-D,
and 1,238 (70 %) on the GAS-Q and the HADS-A. The
proportion of women in the two samples was 64% and
63%, respectively, with a mean age of 45 (SD 17) for
women and 50 (SD 17) years for men. Further demo-
graphic characteristics of patients are shown in Table 1.
The non-complying patients did not differ significantly
from the compliers as to age and gender, which were the
only data at disposal for attrition analyses.
Flow chart study design Figure 1
Flow chart study design.
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Diagnostic criteria and instruments
Psychiatric classification systems like DSM-IV and ICD-10
are based on the presence or absence of various operation-
alized diagnostic criteria. When structured interviews are
used, the patients are asked for the presence of the diag-
nostic criteria by an interviewer. In contrast, in this study
the patients rate themselves the diagnostic criteria for
GAD (DSM-IV) on the Generalized Anxiety Questionnaire
(GAS-Q) and for MDE (DSM-IV) on the Depression
Screening Questionnaire (DSQ), and these patient ratings
are used as diagnostic reference standard in this study.
The GAS-Q is a modification of the Anxiety Screening
Questionnaire [22], and is a self-rating questionnaire
developed to diagnose GAD according to DSM-IV and
ICD-10. The GAS-Q consists of 20 items covering the diag-
nostic criteria for GAD in the DSM-IV. Test-retest reliabil-
ity of the GAS-Q over a two-day retest period showed a
kappa value of 0.74 for the diagnosis of GAD. Congruent
validity comparing GAS-Q diagnosis with the DSM IV
algorithm for GAD of the Composite International Diag-
nostic Interview showed a kappa of 0.72 [23].
The DSQ was made for patient-rating of MDE according
to DSM-IV and ICD-10 [24] and was chosen as our refer-
ence standard. The DSQ is an 11 item questionnaire in
which diagnostic criteria are rated on a three point scale,
supplemented by three questions to assess the age at first
and current episode, and the number of episodes accord-
ing to the criterion A of MDE in DSM-IV. Consistent with
the DSM-IV criteria, a diagnosis of MDE was assigned
when at least five of the items were rated as positive by the
patient. In the German part of the European study, the
internal consistency of the DSQ showed a Cronbach's
coefficient alpha of 0.83 [25]. Test-retest reliability over a
two-day period found a kappa value of 0.82 for MDE [8].
Tests of the DSQ diagnosis versus diagnosis of MDE based
on structured interview showed a kappa 0.89 [26].
The HADS consists of seven items for anxiety (HADS-A)
and seven for depression (HADS-D). The items are scored
on a four-point scale from zero (not present) to three
(considerable). The item scores are added, giving sub-
scale scores on the HADS-A and the HADS-D from zero to
21. In this study valid HADS subscale scores were defined
as having answered at least five of seven items on both the
HADS-A and the HADS-D. In order to be valid in patients
with somatic problems, the HADS items were based on
the psychological aspects of anxiety and depression. The
anxiety items were concentrated on general anxiety, and
five of the items were close to the diagnostic criteria of
GAD. The depression items were based on anhedonia,
which is considered to be one of the essential criteria of
depression [27]. The concurrent validity of the HADS
compared to other questionnaires for anxiety and depres-
sion is described between 0.60 and 0.80 for both sub-
scales [13].
The CGI-S is a standardized assessment tool that is widely
used as an outcome measure in research [28]. The CGI-S
had the following wording: "In your clinical judgement
how severely does this patient suffer from MDE/GAD?"
The ratings of CGI-S were: 1 = not ill at all, 2 = a borderline
case, 3 = only mildly ill, 4 = moderately ill, 5 = seriously
ill and 6 = extremely seriously ill. The CGI-S scale was
dichotomised into 1–2 = not ill, 3–6 = ill, but we also
explored the frequency of cases by a CGI-S score of ≥ 2 (=
borderline case).
Statistical methods
The statistical analyses were carried out with the SPSS for
Windows, version 11.0. Principal Component Analysis
(PCA) with oblique rotation was performed to explore the
factor structure of the HADS. Internal consistency of the
HADS-A and the HADS-D was tested using Cronbach's
coefficient alpha. Pearson's correlation coefficient was
used for estimation of the overlap between the subscales.
Sensitivity and specificity were calculated for different cut-
off values for the HADS-A, the HADS-D, and the CGI-S in
relation to the prevalence rate of GAD identified with
GAS-Q and the rate of MDE identified with DSQ. Sensitiv-
ities and specificities by optimal cut-off were used to cal-
Table 1: Sample characteristics.
Variables DSQ/HADS 
sample N = 1,385
GAS-Q/HADS 
sample N = 1,238
Age, mean (SD):
Female 45.7 (17.3) 45.2 (17.1)
Male 49.8 (17.3) 50.0 (17.7)
N (%) N (%)
Gender:
Female 886 (64.0) 783 (63.2)




934 (68.0) 848 (68.9)
Living alone 440 (32.0) 383 (31.1)
On sick leave:
Yes 248 (20.2) 208 (18.9)
No 980 (79.8) 893 (81.1)
Prevalence rates:
DSQ / GAS-Q 
positive
125 (9.0) 73 (5.9)
HADS-D / HADS-A 
(≥ 8)
256 (18.5) 357 (28.8)
CGI-S (dep / gad, ≥ 3) 337 (24.3) 217 (17.5)BMC Psychiatry 2005, 5:46 http://www.biomedcentral.com/1471-244X/5/46
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culate the rates of true and false positive and negative
cases. The Receiver Operating Characteristics (ROC-curve)
were depicted graphically, and the Area Under the Curve
(AUC) were calculated for the HADS-A, the HADS-D and
the CGI-S against the GAS-Q and the DSQ as reference
standards. The associations of age and gender to caseness
on the instruments were examined by logistic regression
analyses. All significance tests were two-tailed, and p-val-
ues < .05 were reported as significant.
Ethics
The Committee for Medical Ethics of Health Region East
of Norway approved this study. The participants delivered
informed consent after written information about the
study. Wyeth Norway Ltd paid the GPs a fixed sum of EUR
15 per patient in addition to their normal salary. No
employees of Wyeth Ltd. were present in any of the gen-
eral practices during the day of inclusion. The national
study leader coordinated the study, and Wyeth Norway
Ltd functioned as sponsor of the study. This implied that
employees of Wyeth Norway Ltd brought the material for
the study to the GPs and later on collected the forms, but
otherwise had no active part in the study. The company
made no use of the collected data or analyses in their mar-
keting. The study leader and his co-authors had no restric-
tions as to the content of the publications from Wyeth




According to the DSQ, 9.0% (CI 7.6 – 10.7%) of patients
had MDE, and based on the GAS-Q 5.9% (CI 4.7 – 7.4%)
had GAD. Prevalence rates for HAD-D (≥8) and HADS-A
(≥8) were 18.5% (CI 16.5 – 20.6%) and 28.8% (CI 26.3 –
31.5%), respectively. According to GPs' clinical judge-
ment by CGI-S (≥ 3) the prevalence rates were 24.3% (CI
22.1 – 26.7%) for MDE and 17.5% (CI 15.5 – 20.0%) for
GAD. The associations between female gender and CGI-S
caseness of depression (OR 1.5, p = 0.004, CI 1.3–1.9)
and HADS-A caseness of anxiety disorder (OR 1.4, p =
0.013, CI 1.1 – 1.8) were both significant. Age signifi-
cantly reduced the prevalence of caseness with 1–3 % on
DSQ, GAS-Q and HADS-A. Based on a GPs' CGI-S score
cut-off ≥ 2, the prevalence rates were 38% for MDE and
25% for GAD.
Psychometrics of the HADS
The internal consistency of the HADS-A and the HADS-D
showed coefficient alpha of 0.89 and 0.86, respectively.
PCA with varimax rotation of all 14 HADS items,
extracted two factors both with Eigen-value of 4.13, and
that factor solution comprised 59% of the explained vari-
ance. Anxiety and depression items loaded on separate
factors. The anxiety and depression sub-scales shared 54%
of the explained variance.
Case-finding abilities of the HADS
Case-finding abilities for various cut-off values of the
HADS-A and the HADS-D are shown in Table 2. By cut-off
Table 2: Sensitivity and specificity for HADS-A/D and CGI-S.
Generalized Anxiety Disorder 
(N = 1,238)
Major Depressive Episode 
(N = 1,385)
Score N (%) Sensitivity Specificity N (%) Sensitivity Specificity
HADS – A/D 5 637 (51.5) 0.99 0.52 463 (33.4) 0.94 0.73
6 528 (42.6) 0.97 0.61 384 (27.7) 0.89 0.78
7 444 (35.9) 0.92 0.68 301 (21.7) 0.83 0.84
8 357 (28.8) 0.89 0.75 256 (18.5) 0.80 0.88
9 296 (23.9) 0.85 0.80 201 (14.4) 0.74 0.91
10 236 (19.1) 0.71 0.84 156 (11.3) 0.68 0.94
11 198 (16.0) 0.64 0.87 118 (8.5) 0.61 0.97
12 157 (12.7) 0.58 0.90 91 (6.6) 0.50 0.98
13 127 (10.3) 0.47 0.92 64 (4.6) 0.36 0.99
14 95 (7.7) 0.34 0.94 41 (3.0) 0.26 0.99
CGI-S 2 314 (25.4) 0.74 0.78 529 (38.2) 0.93 0.63
3 217 (17.5) 0.52 0.85 337 (24.3) 0.79 0.81
4 141 (11.4) 0.38 0.90 208 (15.0) 0.64 0.90
5 20 (1.6) 0.08 0.99 29 (2.1) 0.14 0.99
6 2 (0.2) 0.00 1.00 2 (0.1) 0.02 1.00BMC Psychiatry 2005, 5:46 http://www.biomedcentral.com/1471-244X/5/46
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score of ≥ 8 on HADS-A, GAD was detected with a sensi-
tivity of 0.89 and a specificity of 0.75. Using the same cut-
off for the HADS-D, MDE cases were detected with a sen-
sitivity of 0.80 and a specificity of 0.88. Identification of
GAD showed an AUC of 0.88 for the HADS-A (Figure 2).
For identification of MDE, the AUC was 0.93 for HADS-D
(Figure 3).
Comparison of GP-rated and patient-rated case 
identification
Using the GPs' CGI-S score of ≥ 3 as cut-off for a positive
diagnosis, GAD was detected with a sensitivity of 0.52 and
a specificity of 0.85 (Table 2). MDE was detected with a
sensitivity of 0.79 and specificity of 0.81 by the same CGI-
S cut-off level. Identification of GAD and MDE with the
CGI-S showed AUCs of 0.77 (Figure 2) and 0.87 (Figure
3), respectively.
Based on the sensitivities and specificities of the HADS-A
by cut-off ≥ 8 and the CGI-S by cut-off ≥ 3 (Table 3) we
found that the true positive disorder rate for the HADS-A
(5.3%) was close to reference standard (5.9%) and signif-
icantly better than for the CGI-S (3.1%). The opposite was
found for the rates of true positive healthy cases. The total
true hit rate of GAD and non-GAD was significantly better
for the GP-rated CGI-S (83%) than for the patient-rated
HADS-A (76%).
For MDE no significant difference was observed between
rates of true positive disorder (Table 3). For true non-
depression rate, the HADS-D (80%) showed a signifi-
cantly better hit rate than the CGI-S (74%). The propor-
tion of totally right classified depressed patients was
significantly better for the patient-rated HADS-D (87%)
than for the GP-rated CGI-S (81%).
Discussion
Strengths and limitations
Compared to former studies from general practice the
high number of patients and GPs in our study is a strength
due to increased variance and reduced biases. The big
sample sizes and a responder-rate above 70% among
patients give adequate statistical power to the performed
analyses. Our sample consists of geographically spread
GPs who's working experience and gender distribution is
representative for GPs in Norway [29]. Patients' age and
gender is representative for patients attending GPs in
Scandinavia [30]. We also consider as a strength that the
GPs were blind to the HADS scores of the patients when
they made their diagnostic evaluations.
It is a weakness of our study that we did not employ struc-
tured interviews for the establishment of reference stand-
ard diagnoses of GAD and MDE. However, the reference
standards used by us comprise the same diagnostic crite-
ria, are well described, and have shown good validity in
relation to structured interviews [23,25]. When both the
HADS and the reference standards are self-rating instru-
ments, the HADS might be systematically biased with
falsely high sensitivity and/or specificity in relation to the
reference standard. On the other hand, an interview could
introduce observer bias in the interpretation of symp-
toms, which is eliminated using self-ratings. The reference
standard questionnaires used in our study gave prevalence
rates for GAD and MDE in general practice that were in
accordance with the prevalence rates reported by Üstün &
Receiver Operating Curves for HADS-D and CGI-S for  detecting MDE Figure 3
Receiver Operating Curves for HADS-D and CGI-S for 
detecting MDE.
ROC Curve for detecting MDE
AUC: HADS-D / CGI-S = 0.93 / 0.87
1 - Specificity
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Receiver Operating Curves for HADS-A and CGI-S for 
detecting GAD.
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Sartorius [1], and this added some validity to our
approach. Our design did not take into account the GPs'
knowledge about the patients' somatic symptoms or psy-
chosocial situation, which could be relevant information
for the GPs in their diagnostic considerations. However,
studies have shown that in non-clinical samples chronic
somatic problems [16] and demographic variations [31]
have only modest influence on the HADS scores.
The use of the CGI-S as a diagnostic instrument could be
discussed since the instrument only evaluates the severity
of the case. Severity is not a clear concept, and it is implicit
in such ratings that the GPs are familiar with both mild
and severe cases of GAD and MDE, although that hardly
is the case. Further, the GPs could be biased in direction
of false positive diagnoses since they took part in a spon-
sored study concerning these mental disorders.
Comparison with existing literature
The internal consistency of the HADS was found in
accordance with other studies [16,13]. The replication of
the original two-factor structure of the HADS among pri-
mary care attenders has been discussed. A Dutch valida-
tion study [32] found evidence for the original two-factor
structure among a sample (n = 112) of consecutive general
practice patients. Data from a large non-clinical popula-
tion give support to a s two-factor-structure of the HADS
[16] in sub-samples with higher mental symptom levels
than in the general population. In our sample from gen-
eral practice, the HADS showed good separation of items,
moderate inter-correlation, and a distinct two-factor struc-
ture. These results support the robustness of the HADS as
a psychometrically adequate self-rating instrument for
patients attending general practice.
An optimal balance between sensitivity and specificity is
requested of a good questionnaire. From a clinical per-
spective high sensitivity might be seen the most important
concern for a screening instrument, giving minimal
number of false negative cases at the sacrifice of some false
positive cases.
In general we found that the patient-rated HADS-A/D had
better diagnostic ability than CGI-S rated by GPs (Figure 2
and 3) in relation to GAD and MDE. However, taking into
regard the prevalence rate of 5.9% of GAD in general prac-
tice, the GPs' ability to recognise people not suffering
from GAD (Table 3) is significant superior to that of the
HADS-A and important in the clinical setting. With a prev-
alence rate of 9% for MDE in general practice the total
proportion of patients correctly identified by HADS-D
was significantly higher than that of GPs using the CGI-S.
Implications for future research or clinical practice
HADS showed satisfying psychometric properties in the
general practice setting, which is of importance for future
research. We found that GPs mainly recognized GAD by
exclusion and MDE by inclusion, but still they had a con-
siderable proportion of misclassifications. GPs' diagnostic
precision in clinical practice is improved by supplement-
ing HADS scores. The advantage of HADS is its feasibility
of completion and well-established cut-off scores for clin-
ically relevant caseness.
Conclusion
The psychometrics of the HADS was found to be excellent
in this sample from general practice. The recommended
cut-off score for caseness on the HADS-A and the HADS-
D of ≥8 seemed appropriate for detecting GAD and MDE
among patients attending primary care. In regard to prev-
alence rates, the GPs should positively trust their sensitiv-
ity in diagnosing MDE, and their specificity in diagnosing
GAD by exclusion of patients without anxiety. Patient-
Table 3: Classification of patients with eventual GAD and MDE.
Generalized Anxiety Disorder (GAS-Q Positive 
73/1,238 = 5.9%)
Major Depressive Episode (DSQ Positive 125/
1,385 = 9.0%)
Patients' HADS-A ≥ 8 GPs' CGI-S ≥ 3 Patients' HADS-D ≥ 8 GPs' CGI-S ≥ 3
Sensitivity / Specificity 0.89 / 0.75 0.52 / 0.85 0.80 / 0.88 0.79 / 0.81
Classification % (95% CI) % (95% CI) % (95% CI) % (95% CI)
True positive disorder 5.3 (4.1–6.5)* 3.1 (2.1–4.1) 7.2 (5.8–8.6) 7.1 (5.7–8.5)
False positive disorder 23.5 (21.1–25.9)* 14.1 (12.2–16.0) 10.9 (9.3–12.5) 17.3 (15.3–19.3)*
Observed disordered 28.8 (26.3–31.3)* 17.2 (15.1–19.3) 18.1 (16.1–20.1) 24.4 (22.1–26.7)*
True positive healthy 70.6 (68.1–73.1) 80.0 (77.8–82.2)* 80.1 (78.0–82.2)* 73.7 (71.4–76.0)
False positive healthy 0.6 (0.2–1.0) 2.8 (1.9–3.7)* 1.8 (1.1–2.5) 1.9 (1.2–2.6)
Observed healthy 71.2 (68.7–73.7) 82.8 (80.7–84.9)* 81.9 (79.9–83.9)* 75.6 (73.3–77.9)
Total rightly classified 75.9 (73.5–78.3) 83.1 (81.0–85.2)* 87.3 (85.5–89.1)* 80.8 (78.7–82.9)
Total wrongly classified 24.1 (21.7–26.5)* 16.9 (14.8–19.0) 12.7 (10.9–14.5) 19.2 (17.1–21.3)*
*The difference shows a statistical significance of p ≤ 0.05BMC Psychiatry 2005, 5:46 http://www.biomedcentral.com/1471-244X/5/46
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rated HADS could represent a useful supplement to GPs'
own clinical judgment.
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